adplus-dvertising
Connect with us

News

Canada secures 2 new deals for possible COVID-19 vaccines – Global News

Published

 on


Canada has inked two additional deals with companies working on a possible vaccine for COVID-19.

The two agreements include 76 million doses of Novavax Inc.’s vaccine candidate and 38 million doses of Johnson & Johnson’s candidate.






1:12
Coronavirus: Government focus is on Canadians’ access to potential COVID-19 vaccine, Trudeau says


Coronavirus: Government focus is on Canadians’ access to potential COVID-19 vaccine, Trudeau says

They bring Canada’s total number of procurement agreements with vaccine developers to four, as deals with Pfizer Canada and Moderna were announced earlier this month.

Story continues below advertisement

Read more:
Canadians could join clinical trials for new COVID-19 vaccine, says researcher

Prime Minister Justin Trudeau acknowledged Monday that there is “a lot more work to go” on the development of any of these vaccines, but said the “broad range of vaccine developers” Canada has signed on with will be beneficial in the long run.

“It’s possible there will be a breakthrough soon, but we don’t know where or when that breakthrough will be,” he said.






0:44
Coronavirus: Trudeau announces 2 new deals for possible COVID-19 vaccines


Coronavirus: Trudeau announces 2 new deals for possible COVID-19 vaccines

“Taken together, our vaccine agreements will give Canada at least 88 million doses with options to obtain tens of millions more.”

Some vaccines may require more than one dose to be effective. Any potential vaccine will be required to pass Health Canada regulatory approval before being distributed.

Story continues below advertisement






2:24
Coronavirus: Canada inks deals with Pfizer, Moderna for coronavirus vaccine candidates


Coronavirus: Canada inks deals with Pfizer, Moderna for coronavirus vaccine candidates

Novavax — a biotechnology company that develops vaccines for serious infectious diseases — said it expects to finalize the advance purchase agreement “as early as the second quarter of 2021.”

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

Novavax’s vaccine (NVX-CoV2373) is currently in its second phase of clinical trials. The company plans to begin the third phase in September.

Johnson & Johnson’s vaccine is currently in phase one and two of its trials in the U.S. and Belgium. In a statement, the company said plans for phase three of the program are already underway, which will include trials on 60,000 volunteers.






2:06
Government of Canada makes vaccine deals with 2 more companies


Government of Canada makes vaccine deals with 2 more companies

Clinical trials by Pfizer Canada, which is working with BioNTech in Germany, and U.S.-based Moderna, have both already advanced to the third stage.

Story continues below advertisement

Canada has requested 20 million and 56 million doses of those candidates, respectively.

Read more:
Canada’s top doctor ‘optimistic’ after Canada-China vaccine partnership collapses

Monday’s announcement is the first glimpse of how many vaccine doses the federal government is working to secure as the coronavirus pandemic continues in Canada. Previously, officials did not elaborate on the number of doses it was requesting from companies, merely saying “millions.”

The cost of the agreements is not yet clear.

Novavax’s vaccine has shown promise in recent weeks. Initial data from an early-stage trial this month exhibited an ability to produce antibodies against COVID-19.

The company recently began enrolling volunteers for its second phase candidate, with data from that part of the clinical trial expected in the fourth quarter of 2020.






2:36
Should the COVID-19 vaccine be patent-free?


Should the COVID-19 vaccine be patent-free?

Globally, the Novavax vaccine is one of nearly 30 being tested in human clinical trials. However, it lags behind candidates from Pfizer, Moderna and AstraZeneca, which are in later stages at this time.

Story continues below advertisement

The United States and Britain are also in deals with Novavax. The U.S. awarded the company $1.6 billion in July to test and manufacture its vaccine in the country, with the hopes of securing 100 million doses by January. Britain has requested to buy 60 million doses.

Johnson & Johnson’s vaccine uses “viral vectors” to generate immune responses. A similar approach is being taken by AstraZeneca, as well as China’s CanSino, which was once being developed in partnership with Canada but has since been abandoned.

Read more:
Safety of COVID-19 vaccine concerning some Canadians, StatCan survey shows

The government also announced on Monday that it would provide $126 million in funding to expand a biomanufacturing facility at the Human Health Therapeutics Research Centre in Montreal.






0:46
Coronavirus: Trudeau announces over $126 million funding to NRC biomanufacturing facility for vaccine production


Coronavirus: Trudeau announces over $126 million funding to NRC biomanufacturing facility for vaccine production

Trudeau said the aid would bolster the facility’s ability to manufacture vaccines and strengthen partnerships with developers. It is expected to be up-and-running by mid-2021, Trudeau said, and intends to produce up to two million doses of vaccine a month by the end of next summer.

Story continues below advertisement

Anita Anand, the minister of public services and procurement, in a statement called the in-principle agreement “an important step” in the government’s efforts to secure a vaccine as the pandemic continues and “evolves.”

As of Aug. 30, the coronavirus pandemic has claimed 9,117 lives in Canada overall, and 127,870 cases have been diagnosed, according to figures released by provincial and territorial governments.

The vast majority of people diagnosed — about 89 per cent — have recovered from the viral illness.

More than 6.3 million tests have been conducted since late January.

— with files from Reuters, the Canadian Press and Global News’ Kerri Breen

© 2020 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)

728x90x4

Source link

News

STD epidemic slows as new syphilis and gonorrhea cases fall in US

Published

 on

 

NEW YORK (AP) — The U.S. syphilis epidemic slowed dramatically last year, gonorrhea cases fell and chlamydia cases remained below prepandemic levels, according to federal data released Tuesday.

The numbers represented some good news about sexually transmitted diseases, which experienced some alarming increases in past years due to declining condom use, inadequate sex education, and reduced testing and treatment when the COVID-19 pandemic hit.

Last year, cases of the most infectious stages of syphilis fell 10% from the year before — the first substantial decline in more than two decades. Gonorrhea cases dropped 7%, marking a second straight year of decline and bringing the number below what it was in 2019.

“I’m encouraged, and it’s been a long time since I felt that way” about the nation’s epidemic of sexually transmitted infections, said the CDC’s Dr. Jonathan Mermin. “Something is working.”

More than 2.4 million cases of syphilis, gonorrhea and chlamydia were diagnosed and reported last year — 1.6 million cases of chlamydia, 600,000 of gonorrhea, and more than 209,000 of syphilis.

Syphilis is a particular concern. For centuries, it was a common but feared infection that could deform the body and end in death. New cases plummeted in the U.S. starting in the 1940s when infection-fighting antibiotics became widely available, and they trended down for a half century after that. By 2002, however, cases began rising again, with men who have sex with other men being disproportionately affected.

The new report found cases of syphilis in their early, most infectious stages dropped 13% among gay and bisexual men. It was the first such drop since the agency began reporting data for that group in the mid-2000s.

However, there was a 12% increase in the rate of cases of unknown- or later-stage syphilis — a reflection of people infected years ago.

Cases of syphilis in newborns, passed on from infected mothers, also rose. There were nearly 4,000 cases, including 279 stillbirths and infant deaths.

“This means pregnant women are not being tested often enough,” said Dr. Jeffrey Klausner, a professor of medicine at the University of Southern California.

What caused some of the STD trends to improve? Several experts say one contributor is the growing use of an antibiotic as a “morning-after pill.” Studies have shown that taking doxycycline within 72 hours of unprotected sex cuts the risk of developing syphilis, gonorrhea and chlamydia.

In June, the CDC started recommending doxycycline as a morning-after pill, specifically for gay and bisexual men and transgender women who recently had an STD diagnosis. But health departments and organizations in some cities had been giving the pills to people for a couple years.

Some experts believe that the 2022 mpox outbreak — which mainly hit gay and bisexual men — may have had a lingering effect on sexual behavior in 2023, or at least on people’s willingness to get tested when strange sores appeared.

Another factor may have been an increase in the number of health workers testing people for infections, doing contact tracing and connecting people to treatment. Congress gave $1.2 billion to expand the workforce over five years, including $600 million to states, cities and territories that get STD prevention funding from CDC.

Last year had the “most activity with that funding throughout the U.S.,” said David Harvey, executive director of the National Coalition of STD Directors.

However, Congress ended the funds early as a part of last year’s debt ceiling deal, cutting off $400 million. Some people already have lost their jobs, said a spokeswoman for Harvey’s organization.

Still, Harvey said he had reasons for optimism, including the growing use of doxycycline and a push for at-home STD test kits.

Also, there are reasons to think the next presidential administration could get behind STD prevention. In 2019, then-President Donald Trump announced a campaign to “eliminate” the U.S. HIV epidemic by 2030. (Federal health officials later clarified that the actual goal was a huge reduction in new infections — fewer than 3,000 a year.)

There were nearly 32,000 new HIV infections in 2022, the CDC estimates. But a boost in public health funding for HIV could also also help bring down other sexually transmitted infections, experts said.

“When the government puts in resources, puts in money, we see declines in STDs,” Klausner said.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Source link

Continue Reading

News

World’s largest active volcano Mauna Loa showed telltale warning signs before erupting in 2022

Published

 on

 

WASHINGTON (AP) — Scientists can’t know precisely when a volcano is about to erupt, but they can sometimes pick up telltale signs.

That happened two years ago with the world’s largest active volcano. About two months before Mauna Loa spewed rivers of glowing orange molten lava, geologists detected small earthquakes nearby and other signs, and they warned residents on Hawaii‘s Big Island.

Now a study of the volcano’s lava confirms their timeline for when the molten rock below was on the move.

“Volcanoes are tricky because we don’t get to watch directly what’s happening inside – we have to look for other signs,” said Erik Klemetti Gonzalez, a volcano expert at Denison University, who was not involved in the study.

Upswelling ground and increased earthquake activity near the volcano resulted from magma rising from lower levels of Earth’s crust to fill chambers beneath the volcano, said Kendra Lynn, a research geologist at the Hawaiian Volcano Observatory and co-author of a new study in Nature Communications.

When pressure was high enough, the magma broke through brittle surface rock and became lava – and the eruption began in late November 2022. Later, researchers collected samples of volcanic rock for analysis.

The chemical makeup of certain crystals within the lava indicated that around 70 days before the eruption, large quantities of molten rock had moved from around 1.9 miles (3 kilometers) to 3 miles (5 kilometers) under the summit to a mile (2 kilometers) or less beneath, the study found. This matched the timeline the geologists had observed with other signs.

The last time Mauna Loa erupted was in 1984. Most of the U.S. volcanoes that scientists consider to be active are found in Hawaii, Alaska and the West Coast.

Worldwide, around 585 volcanoes are considered active.

Scientists can’t predict eruptions, but they can make a “forecast,” said Ben Andrews, who heads the global volcano program at the Smithsonian Institution and who was not involved in the study.

Andrews compared volcano forecasts to weather forecasts – informed “probabilities” that an event will occur. And better data about the past behavior of specific volcanos can help researchers finetune forecasts of future activity, experts say.

(asterisk)We can look for similar patterns in the future and expect that there’s a higher probability of conditions for an eruption happening,” said Klemetti Gonzalez.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

News

Waymo’s robotaxis now open to anyone who wants a driverless ride in Los Angeles

Published

 on

 

Waymo on Tuesday opened its robotaxi service to anyone who wants a ride around Los Angeles, marking another milestone in the evolution of self-driving car technology since the company began as a secret project at Google 15 years ago.

The expansion comes eight months after Waymo began offering rides in Los Angeles to a limited group of passengers chosen from a waiting list that had ballooned to more than 300,000 people. Now, anyone with the Waymo One smartphone app will be able to request a ride around an 80-square-mile (129-square-kilometer) territory spanning the second largest U.S. city.

After Waymo received approval from California regulators to charge for rides 15 months ago, the company initially chose to launch its operations in San Francisco before offering a limited service in Los Angeles.

Before deciding to compete against conventional ride-hailing pioneers Uber and Lyft in California, Waymo unleashed its robotaxis in Phoenix in 2020 and has been steadily extending the reach of its service in that Arizona city ever since.

Driverless rides are proving to be more than just a novelty. Waymo says it now transports more than 50,000 weekly passengers in its robotaxis, a volume of business numbers that helped the company recently raise $5.6 billion from its corporate parent Alphabet and a list of other investors that included venture capital firm Andreesen Horowitz and financial management firm T. Rowe Price.

“Our service has matured quickly and our riders are embracing the many benefits of fully autonomous driving,” Waymo co-CEO Tekedra Mawakana said in a blog post.

Despite its inroads, Waymo is still believed to be losing money. Although Alphabet doesn’t disclose Waymo’s financial results, the robotaxi is a major part of an “Other Bets” division that had suffered an operating loss of $3.3 billion through the first nine months of this year, down from a setback of $4.2 billion at the same time last year.

But Waymo has come a long way since Google began working on self-driving cars in 2009 as part of project “Chauffeur.” Since its 2016 spinoff from Google, Waymo has established itself as the clear leader in a robotaxi industry that’s getting more congested.

Electric auto pioneer Tesla is aiming to launch a rival “Cybercab” service by 2026, although its CEO Elon Musk said he hopes the company can get the required regulatory clearances to operate in Texas and California by next year.

Tesla’s projected timeline for competing against Waymo has been met with skepticism because Musk has made unfulfilled promises about the company’s self-driving car technology for nearly a decade.

Meanwhile, Waymo’s robotaxis have driven more than 20 million fully autonomous miles and provided more than 2 million rides to passengers without encountering a serious accident that resulted in its operations being sidelined.

That safety record is a stark contrast to one of its early rivals, Cruise, a robotaxi service owned by General Motors. Cruise’s California license was suspended last year after one of its driverless cars in San Francisco dragged a jaywalking pedestrian who had been struck by a different car driven by a human.

Cruise is now trying to rebound by joining forces with Uber to make some of its services available next year in U.S. cities that still haven’t been announced. But Waymo also has forged a similar alliance with Uber to dispatch its robotaxi in Atlanta and Austin, Texas next year.

Another robotaxi service, Amazon’s Zoox, is hoping to begin offering driverless rides to the general public in Las Vegas at some point next year before also launching in San Francisco.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending